Sarm1 inhibitors
By designing and applying compounds with specific structures to inhibit SARM1, the treatment challenges of axonal degeneration-related neurological disorders have been solved, enabling effective treatment and prevention of related diseases and reducing the disease burden.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- DISARM THERAPEUTICS INC
- Filing Date
- 2021-08-23
- Publication Date
- 2026-07-17
AI Technical Summary
Current technologies are unable to effectively treat and prevent axonodegenerative neurological disorders, such as peripheral neuropathy, traumatic brain injury, and neurodegenerative diseases, leading to high costs and increased morbidity.
A class of compounds with specific structural formulas I and II are provided, which can inhibit the activity of SARM1 and thus reduce axonal degeneration, including the design, preparation and application methods of the compounds.
By inhibiting SARM1, the compound can reduce axonal degeneration and treat associated neurodegenerative diseases and disorders such as Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, and progressive supranuclear palsy, thereby reducing disease burden and morbidity.
Smart Images
Figure FT_1 
Figure QLYQS_1 
Figure QLYQS_4